Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: A phase II, randomized, double-blind, placebo-controlled study

Timothy W. Schacker, Marcus Conant, Christopher Thoming, Tamara Stanczak, Zengri Wang, Michael Smith, Karl Beutner, Kenneth Fife, Harold Guy, Charles Livengood, S. Parrish, M. Markert, S. Hannon, C. Christiansen, M. Klebe, B. Farladeaux, A. Edgren, T. C. Meng

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Present strategies for control of herpes genitalis recurrences require multiple daily doses of antiviral medication. Imiquimod, an immune response modifier, induces alpha interferon and interleukin-12; application in the presence of local herpes antigens during a recurrence may augment herpes simplex virus (HSV)-specific cell-mediated immunity. To test this theory, we performed a randomized, double-blind, placebo-controlled study of imiquimod 5% cream to assess safety and efficacy for decreasing recurrences. Patients with six or more recurrences of herpes genitalis per year applied study cream (imiquimod or placebo) to lesions one, two, or three times per week for 3 weeks for each recurrence during a 16-week treatment period. This was followed by a 16-week observation period. Of 124 patients randomized to the study, 103 completed the treatment period and 93 completed the observation period. The median times to first genital herpes recurrence were 53 days for those receiving placebo (n = 30) and 54, 60, and 64 days for those receiving imiquimod one time per week (n = 34), two times per week (n = 32), and three times per week (n = 28), respectively. The median annualized recurrence rates during the treatment period were 3.8, 4.9, 3.2, and 3.1, respectively. There were no statistically significant differences in the time to first recurrence or in the annualized recurrence rate between the imiquimod and placebo groups in either the treatment or the observation period. A trend in increased rates of local adverse events at the application site and a delay in lesion healing with more frequent dosing suggested a pharmacologic effect. Although clinical efficacy has been observed for imiquimod in other conditions in which a TH1-type immune response may be beneficial, including other viral infections such as those caused by human papillomavirus, no apparent effect on the short-term natural history of herpes genitalis recurrences was observed.

Original languageEnglish (US)
Pages (from-to)3243-3248
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume46
Issue number10
DOIs
StatePublished - Oct 2002
Externally publishedYes

Fingerprint

imiquimod
Herpes Genitalis
Placebos
Recurrence
Observation
Virus Diseases
Simplexvirus
Therapeutics
Interleukin-12
Interferon-alpha
Cellular Immunity

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis : A phase II, randomized, double-blind, placebo-controlled study. / Schacker, Timothy W.; Conant, Marcus; Thoming, Christopher; Stanczak, Tamara; Wang, Zengri; Smith, Michael; Beutner, Karl; Fife, Kenneth; Guy, Harold; Livengood, Charles; Parrish, S.; Markert, M.; Hannon, S.; Christiansen, C.; Klebe, M.; Farladeaux, B.; Edgren, A.; Meng, T. C.

In: Antimicrobial Agents and Chemotherapy, Vol. 46, No. 10, 10.2002, p. 3243-3248.

Research output: Contribution to journalArticle

Schacker, TW, Conant, M, Thoming, C, Stanczak, T, Wang, Z, Smith, M, Beutner, K, Fife, K, Guy, H, Livengood, C, Parrish, S, Markert, M, Hannon, S, Christiansen, C, Klebe, M, Farladeaux, B, Edgren, A & Meng, TC 2002, 'Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: A phase II, randomized, double-blind, placebo-controlled study', Antimicrobial Agents and Chemotherapy, vol. 46, no. 10, pp. 3243-3248. https://doi.org/10.1128/AAC.46.10.3243-3248.2002
Schacker, Timothy W. ; Conant, Marcus ; Thoming, Christopher ; Stanczak, Tamara ; Wang, Zengri ; Smith, Michael ; Beutner, Karl ; Fife, Kenneth ; Guy, Harold ; Livengood, Charles ; Parrish, S. ; Markert, M. ; Hannon, S. ; Christiansen, C. ; Klebe, M. ; Farladeaux, B. ; Edgren, A. ; Meng, T. C. / Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis : A phase II, randomized, double-blind, placebo-controlled study. In: Antimicrobial Agents and Chemotherapy. 2002 ; Vol. 46, No. 10. pp. 3243-3248.
@article{be439b72e7f344e19bac7efe08b11a68,
title = "Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: A phase II, randomized, double-blind, placebo-controlled study",
abstract = "Present strategies for control of herpes genitalis recurrences require multiple daily doses of antiviral medication. Imiquimod, an immune response modifier, induces alpha interferon and interleukin-12; application in the presence of local herpes antigens during a recurrence may augment herpes simplex virus (HSV)-specific cell-mediated immunity. To test this theory, we performed a randomized, double-blind, placebo-controlled study of imiquimod 5{\%} cream to assess safety and efficacy for decreasing recurrences. Patients with six or more recurrences of herpes genitalis per year applied study cream (imiquimod or placebo) to lesions one, two, or three times per week for 3 weeks for each recurrence during a 16-week treatment period. This was followed by a 16-week observation period. Of 124 patients randomized to the study, 103 completed the treatment period and 93 completed the observation period. The median times to first genital herpes recurrence were 53 days for those receiving placebo (n = 30) and 54, 60, and 64 days for those receiving imiquimod one time per week (n = 34), two times per week (n = 32), and three times per week (n = 28), respectively. The median annualized recurrence rates during the treatment period were 3.8, 4.9, 3.2, and 3.1, respectively. There were no statistically significant differences in the time to first recurrence or in the annualized recurrence rate between the imiquimod and placebo groups in either the treatment or the observation period. A trend in increased rates of local adverse events at the application site and a delay in lesion healing with more frequent dosing suggested a pharmacologic effect. Although clinical efficacy has been observed for imiquimod in other conditions in which a TH1-type immune response may be beneficial, including other viral infections such as those caused by human papillomavirus, no apparent effect on the short-term natural history of herpes genitalis recurrences was observed.",
author = "Schacker, {Timothy W.} and Marcus Conant and Christopher Thoming and Tamara Stanczak and Zengri Wang and Michael Smith and Karl Beutner and Kenneth Fife and Harold Guy and Charles Livengood and S. Parrish and M. Markert and S. Hannon and C. Christiansen and M. Klebe and B. Farladeaux and A. Edgren and Meng, {T. C.}",
year = "2002",
month = "10",
doi = "10.1128/AAC.46.10.3243-3248.2002",
language = "English (US)",
volume = "46",
pages = "3243--3248",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "10",

}

TY - JOUR

T1 - Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis

T2 - A phase II, randomized, double-blind, placebo-controlled study

AU - Schacker, Timothy W.

AU - Conant, Marcus

AU - Thoming, Christopher

AU - Stanczak, Tamara

AU - Wang, Zengri

AU - Smith, Michael

AU - Beutner, Karl

AU - Fife, Kenneth

AU - Guy, Harold

AU - Livengood, Charles

AU - Parrish, S.

AU - Markert, M.

AU - Hannon, S.

AU - Christiansen, C.

AU - Klebe, M.

AU - Farladeaux, B.

AU - Edgren, A.

AU - Meng, T. C.

PY - 2002/10

Y1 - 2002/10

N2 - Present strategies for control of herpes genitalis recurrences require multiple daily doses of antiviral medication. Imiquimod, an immune response modifier, induces alpha interferon and interleukin-12; application in the presence of local herpes antigens during a recurrence may augment herpes simplex virus (HSV)-specific cell-mediated immunity. To test this theory, we performed a randomized, double-blind, placebo-controlled study of imiquimod 5% cream to assess safety and efficacy for decreasing recurrences. Patients with six or more recurrences of herpes genitalis per year applied study cream (imiquimod or placebo) to lesions one, two, or three times per week for 3 weeks for each recurrence during a 16-week treatment period. This was followed by a 16-week observation period. Of 124 patients randomized to the study, 103 completed the treatment period and 93 completed the observation period. The median times to first genital herpes recurrence were 53 days for those receiving placebo (n = 30) and 54, 60, and 64 days for those receiving imiquimod one time per week (n = 34), two times per week (n = 32), and three times per week (n = 28), respectively. The median annualized recurrence rates during the treatment period were 3.8, 4.9, 3.2, and 3.1, respectively. There were no statistically significant differences in the time to first recurrence or in the annualized recurrence rate between the imiquimod and placebo groups in either the treatment or the observation period. A trend in increased rates of local adverse events at the application site and a delay in lesion healing with more frequent dosing suggested a pharmacologic effect. Although clinical efficacy has been observed for imiquimod in other conditions in which a TH1-type immune response may be beneficial, including other viral infections such as those caused by human papillomavirus, no apparent effect on the short-term natural history of herpes genitalis recurrences was observed.

AB - Present strategies for control of herpes genitalis recurrences require multiple daily doses of antiviral medication. Imiquimod, an immune response modifier, induces alpha interferon and interleukin-12; application in the presence of local herpes antigens during a recurrence may augment herpes simplex virus (HSV)-specific cell-mediated immunity. To test this theory, we performed a randomized, double-blind, placebo-controlled study of imiquimod 5% cream to assess safety and efficacy for decreasing recurrences. Patients with six or more recurrences of herpes genitalis per year applied study cream (imiquimod or placebo) to lesions one, two, or three times per week for 3 weeks for each recurrence during a 16-week treatment period. This was followed by a 16-week observation period. Of 124 patients randomized to the study, 103 completed the treatment period and 93 completed the observation period. The median times to first genital herpes recurrence were 53 days for those receiving placebo (n = 30) and 54, 60, and 64 days for those receiving imiquimod one time per week (n = 34), two times per week (n = 32), and three times per week (n = 28), respectively. The median annualized recurrence rates during the treatment period were 3.8, 4.9, 3.2, and 3.1, respectively. There were no statistically significant differences in the time to first recurrence or in the annualized recurrence rate between the imiquimod and placebo groups in either the treatment or the observation period. A trend in increased rates of local adverse events at the application site and a delay in lesion healing with more frequent dosing suggested a pharmacologic effect. Although clinical efficacy has been observed for imiquimod in other conditions in which a TH1-type immune response may be beneficial, including other viral infections such as those caused by human papillomavirus, no apparent effect on the short-term natural history of herpes genitalis recurrences was observed.

UR - http://www.scopus.com/inward/record.url?scp=0036784341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036784341&partnerID=8YFLogxK

U2 - 10.1128/AAC.46.10.3243-3248.2002

DO - 10.1128/AAC.46.10.3243-3248.2002

M3 - Article

C2 - 12234851

AN - SCOPUS:0036784341

VL - 46

SP - 3243

EP - 3248

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 10

ER -